US2023293527A1PendingUtilityA1

Treatment of inflammatory disorders

77
Assignee: ALDEYRA THERAPEUTICS INCPriority: Oct 10, 2017Filed: May 26, 2023Published: Sep 21, 2023
Est. expiryOct 10, 2037(~11.2 yrs left)· nominal 20-yr term from priority
A61K 31/517A61K 31/47A61K 31/423A61K 31/428A61K 31/136A61P 27/04A61P 1/00A61P 9/10A61P 9/12A61P 13/12A61P 25/08A61P 25/28A61P 15/08A61P 27/14A61P 29/00
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 - 13 . (canceled) 
     
     
         14 . A method of treating a disease, disorder, or condition, comprising administering to a subject in need thereof an effective amount of the following compound: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein the disease, disorder, or condition is psoriasis or psoriatic arthritis. 
       
     
     
         15 . The method according to  claim 14 , wherein the disease, disorder, or condition is psoriasis. 
     
     
         16 . The method according to  claim 14 , wherein the disease, disorder, or condition is psoriatic arthritis. 
     
     
         17 . The method according to  claim 14 , wherein the compound or pharmaceutically acceptable salt thereof is administered as a free base. 
     
     
         18 . The method according to  claim 14 , wherein the compound or pharmaceutically acceptable salt thereof is administered systemically to the subject. 
     
     
         19 . The method according to  claim 14 , wherein the compound or pharmaceutically acceptable salt thereof is administered orally to the subject.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.